Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 10/20 | 0.41 |
| ▸ | CTSS | P25774 | 7/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | PPARA | Q07869 | 2/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL873787 | 1.00 | CA1 (0.44) | CA1CA2CA7MEN1GAA | |
| SCHEMBL873398 | 1.00 | CA1 (0.44) | CA1CA2CA7MEN1GAA | |
| SCHEMBL90052 | 0.86 | CA2 (0.50) | CA1CA2CA7MEN1GAA | |
| SCHEMBL83699 | 0.86 | CA2 (0.50) | CA1CA2CA7MEN1GAA | |
| SCHEMBL57432 | 0.86 | CA2 (0.50) | CA1CA2CA7MEN1GAA | |
| SCHEMBL193767 | 0.83 | MEN1 (0.31) | MEN1GAAKMT2ATSHR | |
| SCHEMBL193766 | 0.83 | MEN1 (0.31) | MEN1GAAKMT2ATSHR | |
| SCHEMBL23722683 | 0.82 | CA1 (0.43) | CA1CA2CA7MEN1GAA | |
| SCHEMBL3805811 | 0.82 | CTSK (0.44) | CA1CA2CA7MEN1GAA | |
| SCHEMBL21746358 | 0.82 | CA1 (0.43) | CA1CA2CA7MEN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 189 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118255695-A | Purification method and preparation method of intermediate of beta-lactam compound | 广州艾奇西新药研究有限公司 | 2024-06-28 | — | — | CN | claimed |
| CN-117106189-A | Metal organic framework artificial hydrolase and preparation method and application thereof | 华南理工大学 | 2023-11-24 | — | — | CN | claimed |
| US-12612420-B2 | Arginase inhibitors and methods of use thereof | MOLECURE S.A. (PL) | 2026-04-28 | — | — | US | disclosed |
| US-20260070945-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2026-03-12 | — | — | US | disclosed |
| US-20260022142-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2026-01-22 | — | — | US | disclosed |
| US-20250353817-A1 | INTERLUKIN-17A INHIBITORS AND USES THEREOF | GILEAD SCIENCES INC (US) | 2025-11-20 | — | — | US | disclosed |
| EP-4628488-A1 | CYCLIN K DEGRADER AND USE THEREOF | Adlai Nortye Biopharma Co., Ltd. (CN) | 2025-10-08 | — | — | EP | disclosed |
| US-20250304603-A1 | OXABOROLE ESTERS AND USES THEREOF | ANACOR PHARMACEUTICALS INC (US) | 2025-10-02 | — | — | US | disclosed |
| US-20250250299-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2025-08-07 | — | — | US | disclosed |
| US-20250243196-A1 | CITRON KINASE INHIBITORS | THE CLEVELAND CLINIC FOUNDATION | 2025-07-31 | — | — | US | disclosed |
| US-20250163104-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2025-05-22 | — | — | US | disclosed |
| US-20080267916-A1 | CYCLIC P3 TRIPEPTIDE HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-10-30 | — | — | US | disclosed |
| US-20080267916-A1 | CYCLIC P3 TRIPEPTIDE HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-10-30 | — | — | US | disclosed |
| US-20080050336-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2008-02-28 | — | — | US | disclosed |
| WO-2008021927-A2 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-02-21 | — | — | WO | disclosed |
| US-20070093501-A1 | Urea derivative, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-04-26 | — | — | US | disclosed |
| EP-1695961-A1 | UREA DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Pharmaceutical Company Limited (JP) | 2006-08-30 | — | — | EP | disclosed |
| US-4812564-A | Process for preparing 4,4-dialkyl-2-azetidinones utilizing a pyridine (or substituted pyridine) sulfur trioxide complex | E. R. SQUIBB & SONS, INC. (US) | 1989-03-14 | — | — | US | disclosed |
| US-4694083-A | Certain carbamate ester derivatives forming salts with pyridinium or picolinium cations which are useful as intermediates | E. R. SQUIBB & SONS, INC. (US) | 1987-09-15 | — | — | US | disclosed |
| US-4638061-A | [3S(Z)]-2-[[[1-(2-amino-4-thiazolyl)-2-[[2,2-dimethyl-4-oxo-1-(sulfooxy)-3-azetidinyl]amino]-2-oxoethylidene]-amino]oxy] acetic acid and intermediate | E. R. SQUIBB & SONS, INC. (US) | 1987-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250304603-A1 | OXABOROLE ESTERS AND USES THEREOF | OXA1L, HSD17B12, OXER1 | CA1 3605/4885CA2 2852/4885CA7 1366/4885 |
| US-20250163104-A1 | MACROCYCLIC IMMUNOMODULATORS | CD274, PDCD1LG2, PDCD1 | CA1 4882/4885CA2 4875/4885CA7 4861/4885 |
| US-20250353817-A1 | INTERLUKIN-17A INHIBITORS AND USES THEREOF | IL17A, IL15, IL23R | CA1 4798/4885CA2 4754/4885CA7 2321/4885 |
| US-20080050336-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | CA1 4434/4885CA2 4556/4885CA7 4114/4885 |
| US-20260022142-A1 | MACROCYCLIC IMMUNOMODULATORS | CD274, PDCD1LG2, PDCD1 | CA1 4465/4885CA2 3665/4885CA7 3261/4885 |
| US-20260070945-A1 | MACROCYCLIC IMMUNOMODULATORS | CD274, PDCD1, PDCD1LG2 | CA1 4521/4885CA2 3067/4885CA7 2780/4885 |
| US-20250250299-A1 | MACROCYCLIC IMMUNOMODULATORS | CD274, PDCD1LG2, PDCD1 | CA1 4882/4885CA2 4881/4885CA7 4876/4885 |
| US-20250243196-A1 | CITRON KINASE INHIBITORS | CHEK2, CILK1, DCK | CA1 1132/4885CA2 1566/4885CA7 1177/4885 |
| US-12612420-B2 | Arginase inhibitors and methods of use thereof | ARG1, ARG2, ARGLU1 | CA1 600/4885CA2 204/4885CA7 2113/4885 |
| US-20070093501-A1 | Urea derivative, process for producing the same, and use | F2, URB2, F12 | CA1 3881/4885CA2 2498/4885CA7 3286/4885 |
| US-20080267916-A1 | CYCLIC P3 TRIPEPTIDE HEPATITIS C SERINE PROTEASE INHIBITORS | PRSS1, CTSC, PREP | CA1 1032/4885CA2 2027/4885CA7 2245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.